$24.89
▲ +0.3% Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
lean bull
▲ 3
● 22
▼ 0
What to Watch in Pfizer's Non-Oncology Portfolio This Earnings Season
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
Overview
52-week range
$23
$29
32% of range
Avg surprise (last 3)
+28.0%
Avg reaction (last 2)
+1.9%
100% positive
Latest IV / EM
51%
EM ±3.0% · $25 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $0.75 | $0.71 | +5.6% | -18.5% | +0.6% | earnings |
| Sun Sep 28, 2025 | Sep 2025 | $0.62 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $0.78 | $0.58 | +34.5% | — | — | earnings |
| Tue Apr 29, 2025 | Mar/2025 | $0.92 | $0.64 | +43.8% | — | +3.2% | earnings |
| Sun Sep 29, 2024 | Sep 2024 | $0.78 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.01 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.55 | — | — | — | — | financials |
| Sun Oct 1, 2023 | Oct 2023 | $-0.42 | — | — | — | — | financials |
| Sun Jul 2, 2023 | Jul 2023 | $0.41 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | BMO | $0.68 | $0.78 | -12.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.45B | — | $16.65B | $14.65B | $13.71B | — | $17.70B | $13.28B |
| Cost of revenue | $3.55B | — | $4.17B | $3.78B | $2.85B | — | $5.26B | $3.30B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $2.69B | — | $3.54B | $2.91B | $2.97B | — | $4.46B | $41M |
| EPS (diluted) | $0.47 | — | $0.62 | $0.51 | $0.52 | — | $0.78 | $0.01 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.70B | $1.14B | $1.34B | $1.64B | $1.43B | $1.04B | $1.09B | $1.05B |
| Inventory | $10.67B | $10.65B | $11.47B | $11.67B | $10.85B | $10.85B | $11.72B | $11.45B |
| Total current assets | $42.82B | $42.90B | $46.92B | $43.70B | $45.86B | $50.36B | $43.22B | $37.83B |
| Total assets | $207.62B | $208.16B | $208.73B | $206.09B | $208.03B | $213.40B | $219.48B | $216.19B |
| Long-term debt | $60.56B | $61.64B | $57.41B | $57.50B | $57.64B | $57.41B | $58.00B | $57.51B |
| Total liabilities | $117.21B | $121.39B | $115.64B | $117.08B | $117.39B | $124.90B | $126.92B | $128.22B |
| Total equity | $90.10B | $86.48B | $92.80B | $88.69B | $90.34B | $88.20B | $92.29B | $87.70B |